Genetic Counseling

Halo Diagnostics, Ikonopedia Partner to Provide Genetic Testing for Breast Cancer.
[No author given]
Precision Oncology News. 2022 Nov 28.

LitAlert ~~ GeneLit.com

BRCAShare-Assessment of an animated digital message for intrafamilial communication of pathogenic variant positive test results: A feasibility study.
Aeilts AM, Carpenter KM, Hovick SR, Byrne L, Shoben AB, Senter L.
J Genet Couns. 2022 Nov 25. doi: 10.1002/jgc4.1656. Epub ahead of print.

Testing a deliberative democracy method with citizens of African ancestry to weigh pros and cons of targeted screening for hereditary breast and ovarian cancer risk.
Guan Y, Pathak S, Ballard D, Veluswamy JK, McCullough LE, McBride CM, Gornick MC.
Front Public Health. 2022 Nov 8;10:984926. doi: 10.3389/fpubh.2022.984926.

Nest Genomics Building EHR-Integrated Clinical Decision Support for Genetics-Informed Care.
Cohen JK.
GenomeWeb. Disease Areas. Cancer. 2022 Oct 25.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer.
[No author given]
GenomeWeb. The Scan. 2022 Nov 23.

•• Original research:

A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.

Fatalism and metaphor in Confucianism: A qualitative study of barriers to genetic testing among first-degree relatives of hereditary cancer patients from China.
Jiang C, Liu L, Wang Y, Wu L, Zhang W, Wu X.
Psychooncology. 2022 Nov 15. doi: 10.1002/pon.6068. Epub ahead of print.

Latinx attitudes, barriers, and experiences with genetic counseling and testing: A systematic review.
Dron HA, Bucio D, Young JL, Tabor HK, Cho MK.
J Genet Couns. 2022 Oct 27. doi: 10.1002/jgc4.1632. Epub ahead of print.

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.

Development of a web-based, theory-guided narrative intervention for women at elevated risk for breast cancer.
Katz ML, Senter L, Reiter PL, Emerson B, Ennis AC, Shane-Carson KP, Aeilts A, Cassingham HR, Schnell PM, Agnese DM, Toland AE, Sweet K.
Patient Educ Couns. 2022 Oct 29:S0738-3991(22)00820-5. doi: 10.1016/j.pec.2022.10.348. Epub ahead of print.

Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
Fam Cancer. 2022 Oct 20. doi: 10.1007/s10689-022-00317-w. Epub ahead of print.

Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.

Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort.
Sarki M, Ming C, Aceti M, Fink G, Aissaoui S, Bürki N, Graffeo R, Heinimann K, Zufferey MC, Monnerat C, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC.
J Pers Med. 2022 Oct 19;12(10):1740. doi: 10.3390/jpm12101740.

How should we address the inevitable harms from non-negligent variant reclassification in predictive genetic testing?
Rashkin M, Kingham K, Lara-Otero , Mckenna M, Villiers J, Worthington MM, Prince A.
J Genet Couns. 2022 Oct 19. doi: 10.1002/jgc4.1638. Epub ahead of print.

Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
Bhardwaj PV, Abdou YG.
Curr Oncol Rep. 2022 Oct 18. doi: 10.1007/s11912-022-01340-x. Epub ahead of print.